Literature DB >> 8573369

Hydroxyurea and AIDS: an old drug finds a new application?

F Lori1, R C Gallo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8573369     DOI： 10.1089/aid.1995.11.1149

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  6 in total

1.  Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  N K Back; B Berkhout
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

2.  Hydroxyurea: A useful adjunct to the standard antiviral therapy in chronic hepatitis B.

Authors:  Mostafa Alavi-Moghaddam
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

3.  Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Authors:  N K Back; M Nijhuis; W Keulen; C A Boucher; B O Oude Essink; A B van Kuilenburg; A H van Gennip; B Berkhout
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

4.  The effect of hydroxyurea on the phosphorylation of zidovudine and lamivudine in human umbilical vein endothelial cells.

Authors:  Timothy R McGuire; Eric B Hoie; Konstantine K Manouilov; Peter G Gwilt
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

Review 5.  Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Authors:  Julianna Lisziewicz; Andrea Foli; Mark Wainberg; Franco Lori
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

Authors:  Susan Swindells; Calvin J Cohen; Daniel S Berger; Karen T Tashima; Qiming Liao; Bonnie F Pobiner; Jerry W Snidow; Gary E Pakes; Jaime E Hernandez
Journal:  BMC Infect Dis       Date:  2005-04-08       Impact factor: 3.090
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.